001     169831
005     20240229133656.0
024 7 _ |a 10.1093/ije/dyab115
|2 doi
024 7 _ |a pmid:34259837
|2 pmid
024 7 _ |a 0300-5771
|2 ISSN
024 7 _ |a 1464-3685
|2 ISSN
024 7 _ |a altmetric:109501836
|2 altmetric
037 _ _ |a DKFZ-2021-01575
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Porta, Miquel
|0 0000-0003-1684-7428
|b 0
245 _ _ |a Plasma concentrations of persistent organic pollutants and pancreatic cancer risk.
260 _ _ |a Oxford
|c 2022
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1652441767_26048
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2022 May 9;51(2):479-490
520 _ _ |a Findings and limitations of previous studies on persistent organic pollutants (POPs) and pancreatic cancer risk support conducting further research in prospective cohorts.We conducted a prospective case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Participants were 513 pancreatic cancer cases and 1020 matched controls. Concentrations of 22 POPs were measured in plasma collected at baseline.Some associations were observed at higher concentrations of p, p'-DDT, trans-nonachlor, β-hexachlorocyclohexane and the sum of six organochlorine pesticides and of 16 POPs. The odds ratio (OR) for the upper quartile of trans-nonachlor was 1.55 (95% confidence interval 1.06-2.26; P for trend = 0.025). Associations were stronger in the groups predefined as most valid (participants having fasted >6 h, with microscopic diagnostic confirmation, normal weight, and never smokers), and as most relevant (follow-up ≥10 years). Among participants having fasted >6 h, the ORs were relevant for 10 of 11 exposures. Higher ORs were also observed among cases with microscopic confirmation than in cases with a clinical diagnosis, and among normal-weight participants than in the rest of participants. Among participants with a follow-up ≥10 years, estimates were higher than in participants with a shorter follow-up (for trans-nonachlor: OR = 2.14, 1.01 to 4.53, P for trend = 0.035). Overall, trans-nonachlor, three PCBs and the two sums of POPs were the exposures most clearly associated with pancreatic cancer risk.Individually or in combination, most of the 22 POPs analysed did not or only moderately increased the risk of pancreatic cancer.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Pancreatic cancer
|2 Other
650 _ 7 |a biomarkers
|2 Other
650 _ 7 |a environmental health
|2 Other
650 _ 7 |a methods
|2 Other
650 _ 7 |a persistent organic pollutants
|2 Other
700 1 _ |a Gasull, Magda
|b 1
700 1 _ |a Pumarega, José
|b 2
700 1 _ |a Kiviranta, Hannu
|b 3
700 1 _ |a Rantakokko, Panu
|b 4
700 1 _ |a Raaschou-Nielsen, Ole
|b 5
700 1 _ |a Bergdahl, Ingvar A
|b 6
700 1 _ |a Sandanger, Torkjel Manning
|b 7
700 1 _ |a Agudo, Antoni
|b 8
700 1 _ |a Rylander, Charlotta
|b 9
700 1 _ |a Nøst, Therese Haugdahl
|b 10
700 1 _ |a Donat-Vargas, Carolina
|b 11
700 1 _ |a Aune, Dagfinn
|b 12
700 1 _ |a Heath, Alicia K
|b 13
700 1 _ |a Cirera, Lluís
|b 14
700 1 _ |a Goñi-Irigoyen, Fernando
|b 15
700 1 _ |a Alguacil, Juan
|b 16
700 1 _ |a Giménez-Robert, Àlex
|b 17
700 1 _ |a Tjønneland, Anne
|b 18
700 1 _ |a Sund, Malin
|b 19
700 1 _ |a Overvad, Kim
|b 20
700 1 _ |a Mancini, Francesca Romana
|b 21
700 1 _ |a Rebours, Vinciane
|b 22
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 23
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 24
|u dkfz
700 1 _ |a Schulze, Matthias B
|b 25
700 1 _ |a Trichopoulou, Antonia
|b 26
700 1 _ |a Palli, Domenico
|b 27
700 1 _ |a Grioni, Sara
|b 28
700 1 _ |a Tumino, Rosario
|b 29
700 1 _ |a Naccarati, Alessio
|b 30
700 1 _ |a Panico, Salvatore
|b 31
700 1 _ |a Vermeulen, Roel
|b 32
700 1 _ |a Quirós, J Ramón
|b 33
700 1 _ |a Rodríguez-Barranco, Miguel
|b 34
700 1 _ |a Colorado-Yohar, Sandra M
|b 35
700 1 _ |a Chirlaque, María-Dolores
|b 36
700 1 _ |a Ardanaz, Eva
|b 37
700 1 _ |a Wareham, Nick
|b 38
700 1 _ |a Key, Tim
|b 39
700 1 _ |a Johansson, Mattias
|b 40
700 1 _ |a Murphy, Neil
|b 41
700 1 _ |a Ferrari, Pietro
|b 42
700 1 _ |a Huybrechts, Inge
|b 43
700 1 _ |a Chajes, Veronique
|b 44
700 1 _ |a Gonzalez, Carlos Alberto
|b 45
700 1 _ |a de-Mesquita, Bas Bueno-
|b 46
700 1 _ |a Gunter, Marc
|b 47
700 1 _ |a Weiderpass, Elisabete
|b 48
700 1 _ |a Riboli, Elio
|b 49
700 1 _ |a Duell, Eric J
|b 50
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 51
|u dkfz
700 1 _ |a Vineis, Paolo
|0 0000-0001-8935-4566
|b 52
773 _ _ |a 10.1093/ije/dyab115
|g p. dyab115
|0 PERI:(DE-600)1494592-7
|n 2
|p 479-490
|t International journal of epidemiology
|v 51
|y 2022
|x 1464-3685
909 C O |p VDB
|o oai:inrepo02.dkfz.de:169831
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 51
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-02-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-02-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-02-04
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-08
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-08
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J EPIDEMIOL : 2021
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-08
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-08
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J EPIDEMIOL : 2021
|d 2022-11-08
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21